Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $6.4 million.

  • Collegium Pharmaceutical's Other Accumulated Expenses rose 3141.62% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 3141.62%. This contributed to the annual value of $4.8 million for FY2024, which is 3216.67% up from last year.
  • According to the latest figures from Q3 2025, Collegium Pharmaceutical's Other Accumulated Expenses is $6.4 million, which was up 3141.62% from $4.3 million recorded in Q2 2025.
  • Collegium Pharmaceutical's Other Accumulated Expenses' 5-year high stood at $6.4 million during Q3 2025, with a 5-year trough of $578000.0 in Q1 2021.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $3.4 million (2022), whereas its average is $3.4 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first tumbled by 6373.9% in 2021, then skyrocketed by 81660.9% in 2022.
  • Quarter analysis of 5 years shows Collegium Pharmaceutical's Other Accumulated Expenses stood at $2.8 million in 2021, then grew by 21.28% to $3.4 million in 2022, then rose by 4.41% to $3.6 million in 2023, then soared by 32.17% to $4.8 million in 2024, then skyrocketed by 33.98% to $6.4 million in 2025.
  • Its Other Accumulated Expenses was $6.4 million in Q3 2025, compared to $4.3 million in Q2 2025 and $4.8 million in Q1 2025.